{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T02:24:08Z","timestamp":1773368648436,"version":"3.50.1"},"reference-count":31,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002632","name":"Hallym University Research Fund","doi-asserted-by":"publisher","award":["HURF-2024-38"],"award-info":[{"award-number":["HURF-2024-38"]}],"id":[{"id":"10.13039\/501100002632","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Dual-phase amyloid PET imaging has been proposed to provide complementary information regarding amyloid burden and cerebral perfusion. This exploratory pilot study evaluated whether semiquantitative parameters derived from dual-phase PET\/CT could differentiate individuals operationally classified as Alzheimer\u2019s disease with mild functional impairment (AD-MFI) from those with mild cognitive impairment (MCI). Materials and Methods: Twenty-four participants (AD-MFI, n = 19; MCI, n = 5) underwent dual-phase amyloid PET\/CT and structural MRI. Early phase SUV (eSUV), delayed-phase SUV (dSUV), standardized uptake value ratios (SUVR), and the difference between early and delayed uptake (SUVdiff) were analyzed across predefined cortical regions. Group differences were assessed using nonparametric tests, with false discovery rate (FDR) and Bonferroni corrections applied for multiple comparisons. Diagnostic performance was evaluated using receiver operating characteristic (ROC) curve analysis. Results: Several regional parameters demonstrated nominally significant group differences in uncorrected analyses; however, none remained statistically significant after correction for multiple comparisons. Among the evaluated metrics, SUVdiff demonstrated the highest diagnostic performance (sensitivity 84.2%, specificity 80.0%), followed by eSUV (68.4%, 100%) and MRI cortical volume (47.4%, 100%). Delayed-phase parameters alone showed limited discriminatory robustness despite observed group-level differences. Conclusions: In this exploratory cohort, SUVdiff showed moderate discriminatory potential between AD-MFI and MCI. However, given the small sample size and multiplicity of comparisons, the results should be interpreted as hypothesis-generating. Larger, prospective studies are required to determine the reproducibility and clinical utility of dual-phase semiquantitative parameters.<\/jats:p>","DOI":"10.3390\/medicina62030529","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T13:12:24Z","timestamp":1773321144000},"page":"529","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Differentiating Early Alzheimer\u2019s Disease from MCI Using Comprehensive Semiquantitative Parameters in Dual-Phase Amyloid PET: A Pilot Study"],"prefix":"10.3390","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2003-813X","authenticated-orcid":false,"given":"Hyung Jin","family":"Choi","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Chuncheon Sacred Heart Hospital, College of Medicine, Hallym University, 77 Sakju-ro, Chuncheon-si 24253, Gangwon-do, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ara","family":"Cho","sequence":"additional","affiliation":[{"name":"Mind-Neuromodulation Laboratory, College of Medicine, Hallym University, Chuncheon-si 24252, Gangwon-do, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3034-1485","authenticated-orcid":false,"given":"Joung Hyun","family":"You","sequence":"additional","affiliation":[{"name":"Mind-Neuromodulation Laboratory, College of Medicine, Hallym University, Chuncheon-si 24252, Gangwon-do, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seungchan","family":"Park","sequence":"additional","affiliation":[{"name":"Mind-Neuromodulation Laboratory, College of Medicine, Hallym University, Chuncheon-si 24252, Gangwon-do, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4580-3918","authenticated-orcid":false,"given":"Suk Hyun","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Radiology, Hallym University Kangnam Sacred Heart Hospital, College of Medicine, Hallym University, Seoul 07441, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Do Hoon","family":"Kim","sequence":"additional","affiliation":[{"name":"Mind-Neuromodulation Laboratory, College of Medicine, Hallym University, Chuncheon-si 24252, Gangwon-do, Republic of Korea"},{"name":"Department of Psychiatry, Hallym University Chuncheon Sacred Heart Hospital, College of Medicine, Hallym University, 77 Sakju-ro, Chuncheon-si 24253, Gangwon-do, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2025, March 30). Dementia: Key Facts, Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dementia."},{"key":"ref_2","unstructured":"Alzheimer\u2019s Disease International (2024). Global Changes in Attitudes to Dementia, Alzheimer\u2019s Disease International. World Alzheimer Report."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.bcp.2013.12.024","article-title":"Alzheimer disease: Epidemiology, diagnostic criteria, risk factors and biomarkers","volume":"88","author":"Reitz","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1001\/archneur.56.3.303","article-title":"Mild cognitive impairment: Clinical characterization and outcome","volume":"56","author":"Petersen","year":"1999","journal-title":"Arch. Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1056\/NEJMcp0910237","article-title":"Clinical practice. Mild cognitive impairment","volume":"364","author":"Petersen","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/S0140-6736(06)68542-5","article-title":"Mild cognitive impairment","volume":"367","author":"Gauthier","year":"2006","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1159\/000354370","article-title":"Rate of conversion from prodromal Alzheimer\u2019s disease to Alzheimer\u2019s dementia: A systematic review of the literature","volume":"3","author":"Ward","year":"2013","journal-title":"Dement. Geriatr. Cogn. Disord. Extra"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in Early Alzheimer\u2019s Disease","volume":"388","author":"Swanson","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Wang, Q., Chen, S., Wang, J., Shang, H., and Chen, X. (2024). Advancements in Pharmacological Treatment of Alzheimer\u2019s Disease: The Advent of Disease-Modifying Therapies (DMTs). Brain Sci., 14.","DOI":"10.3390\/brainsci14100990"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s13139-024-00848-3","article-title":"Anti-amyloid Antibody Therapies for Alzheimer\u2019s Disease","volume":"58","author":"Park","year":"2024","journal-title":"Nucl. Med. Mol. Imaging"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jalz.2015.02.004","article-title":"Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer\u2019s disease: Phase 3 study","volume":"11","author":"Sabri","year":"2015","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e2850","DOI":"10.1002\/brb3.2850","article-title":"Amyloid-beta PET in Alzheimer\u2019s disease: A systematic review and Bayesian meta-analysis","volume":"13","author":"Ruan","year":"2023","journal-title":"Brain Behav."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","article-title":"Tracking pathophysiological processes in Alzheimer\u2019s disease: An updated hypothetical model of dynamic biomarkers","volume":"12","author":"Jack","year":"2013","journal-title":"Lancet Neurol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S1474-4422(22)00168-5","article-title":"Tau biomarkers in Alzheimer\u2019s disease: Towards implementation in clinical practice and trials","volume":"21","author":"Ossenkoppele","year":"2022","journal-title":"Lancet Neurol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e70111","DOI":"10.1002\/brb3.70111","article-title":"Comparative Diagnostic Performance of Amyloid-Beta Positron Emission Tomography and Magnetic Resonance Imaging in Alzheimer\u2019s Disease: A Head-to-Head Meta-Analysis","volume":"14","author":"Li","year":"2024","journal-title":"Brain Behav."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Hatashita, S., and Yamasaki, H. (2013). Diagnosed mild cognitive impairment due to Alzheimer\u2019s disease with PET biomarkers of beta amyloid and neuronal dysfunction. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0066877"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"102773","DOI":"10.1016\/j.nicl.2021.102773","article-title":"Dual-phase (18)F-florbetaben PET provides cerebral perfusion proxy along with beta-amyloid burden in Alzheimer\u2019s disease","volume":"31","author":"Yoon","year":"2021","journal-title":"Neuroimage Clin."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1007\/s00259-016-3359-8","article-title":"Imaging characteristic of dual-phase (18)F-florbetapir (AV-45\/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer\u2019s disease and mild cognitive impairment","volume":"43","author":"Lin","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s12149-018-1292-6","article-title":"SPECT and PET imaging in Alzheimer\u2019s disease","volume":"32","author":"Valotassiou","year":"2018","journal-title":"Ann. Nucl. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s13139-024-00840-x","article-title":"Imaging Procedure and Clinical Studies of [(18)F]FP-CIT PET","volume":"58","author":"Sung","year":"2024","journal-title":"Nucl. Med. Mol. Imaging"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s13139-024-00865-2","article-title":"Are the Nuclear Neuro-Imaging Biomarkers Reliable?","volume":"58","author":"Bom","year":"2024","journal-title":"Nucl. Med. Mol. Imaging"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13550-019-0499-4","article-title":"Optimized dual-time-window protocols for quantitative [(18)F]flutemetamol and [(18)F]florbetaben PET studies","volume":"9","author":"Heeman","year":"2019","journal-title":"EJNMMI Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuroimage.2010.06.010","article-title":"Automatic parcellation of human cortical gyri and sulci using standard anatomical nomenclature","volume":"53","author":"Destrieux","year":"2010","journal-title":"Neuroimage"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/jmri.26810","article-title":"Increased cerebral blood flow with increased amyloid burden in the preclinical phase of Alzheimer\u2019s disease","volume":"51","author":"Fazlollahi","year":"2020","journal-title":"J. Magn. Reson. Imaging"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"18480","DOI":"10.1038\/s41598-024-68916-4","article-title":"Elevated cerebral blood flow proxy with increased beta-amyloid burden in Alzheimer\u2019s disease preclinical phase evaluated by dual-phase (18)F-florbetaben positron emission tomography","volume":"14","author":"Kim","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1474-4422(11)70077-1","article-title":"Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer\u2019s disease and healthy controls: A multicentre phase 2 diagnostic study","volume":"10","author":"Barthel","year":"2011","journal-title":"Lancet Neurol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.3233\/JAD-180522","article-title":"Dual Time-Point [18F]Florbetaben PET Delivers Dual Biomarker Information in Mild Cognitive Impairment and Alzheimer\u2019s Disease","volume":"66","author":"Florek","year":"2018","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Kadir, A., Almkvist, O., Forsberg, A., Wall, A., Engler, H., Langstrom, B., and Nordberg, A. (2012). Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer\u2019s disease. Neurobiol. Aging, 33.","DOI":"10.1016\/j.neurobiolaging.2010.06.015"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.nicl.2016.10.005","article-title":"Evaluation of early-phase [(18)F]-florbetaben PET acquisition in clinical routine cases","volume":"14","author":"Daerr","year":"2017","journal-title":"Neuroimage Clin."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/3\/529\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T14:44:45Z","timestamp":1773326685000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/3\/529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":31,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["medicina62030529"],"URL":"https:\/\/doi.org\/10.3390\/medicina62030529","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]}}}